Global Stem Cells Group Subsidiary Adimarket to Launch Progenikine™ SVF Closed System
Adimarket, a subsidiary of Global Stem Cells Group, Inc., is preparing to launch Progenikine™, its new and approved SVF closed system kit using EmCyte technology, which is expected to be available to physicians July 2016. The Progenikine kit contains all of the elements necessary to process adipose tissue and obtain stromal vascular fraction (SVF) in a closed environment.
Adipose derived stem cells (ASCs) are used by physicians for a variety of indications. Most commonly, 
ASCs are isolated at the point of care from lipoaspirate (derived from liposuction) tissue as the stromal vascular fraction (SVF), harvested from the patient and immediately administered to the patient as an injection, or used to enrich fat grafts. Isolation of ASCs from adipose tissue is a relatively simple process performed routinely in cell biology laboratories, but isolation at the point of care for immediate clinical administration requires special methodology to prevent contamination, ensuring the integrity of the clinical procedure, and complying with regulatory requirements.
Developed in conjunction with Patrick Pennie, Emcyte CEO, and Maritza Novas, Director of Research and Development
for Global Stem Cells Group, Progenikine fuses elements from Emcyte systems with the Global Stem Cells Group SVF protocols. The kit can provide a low cost, rapid and simple alternative to traditional methods of isolating ASCs, particularly when smaller quantities are needed.
“We’re excited to launch the Progenikine kit, the newest product designed to help Global Stem Cells Group fulfill its mission to provide accessible products to our member clients,” says Benito Novas, CEO of Global Stem Cells Group. “These are the milestones that bring us closer to ensuring that more patients will be able to gain access to stem cell 
therapies.”
To learn more about the Progenikine kit, visit the Global Stem Cells Group website, email bnovas(at)stemcellsgroup(dot)com, or call 305-560-5337.
About Global Stem Cells Group:
Global Stem Cells Group, Inc. is the parent company of six wholly owned operating companies dedicated entirely to stem cell research, training, products and solutions. Founded in 2012, the company combines dedicated researchers, physician and patient educators and solution providers with the shared goal of meeting the growing worldwide need for leading edge stem cell treatments and solutions.
With a singular focus on this exciting new area of medical research, Global Stem Cells Group and its subsidiaries are uniquely positioned to become global leaders in cellular medicine.
Global Stem Cells Group’s corporate mission is to make the promise of stem cell medicine a reality for patients around the world. With each of GSCGs six operating companies focused on a separate research-based mission, the result is a global network of state-of-the-art stem cell treatments.
About Adimarket:
Adimarket, Inc., a division of the Global Stem Cells Group, is a cost-competitive online marketplace for quality regenerative medicine equipment and supplies for physicians and health care professionals.
Adimarket was founded to provide physicians and other health care professionals with the tools they need to practice regenerative medicine in a medical office setting. Motivated by a firm belief in the impact the practice of stem cell medicine can have when dispensed in a doctor’s office, Adimarket provides physicians with the tools they need to provide patients with cutting edge treatments.
Adimarket’s experienced customer service representatives provide valuable guidance and advice regarding products relevant to individual practices.
About Emcyte:
Fort Myers, Florida-based EmCyte Corporation is a leader in autologous cellular biologics with the GenesisCS Component Concentrating Systems. These systems provide patients with the best opportunity for rapid recovery and provide practitioners with the most advanced clinical point of care experience. EmCyte systems are developed to meet every clinical requirement, giving the physician better clinical choices. EmCyte devices have been independently reviewed and show to produce buffycoat concentrations of 6x to greater than 10x baseline in 7mLs, with yields ranging from 70 percent to greater than 90 percent.
EmCyte technology allows for the safe extraction of concentrated platelets and other regenerative cell types from the patient’s own blood. These cells are then re-suspended in a small volume of the patient’s blood plasma and then applied to the treatment site.
###
To view this press release live online, click here
- Published in Press Releases
Global Stem Cells Group Announces Cell Assisted Fat Transfer Training
MIAMI, April 30, 2016–Global Stem Cells Group and Stem Cell Training, Inc. have announced the addition of a cell assisted fat transfer training course, to be conducted by Alfredo Hoyos, M.D., head of the GSCG Advisory Board, and Enrique Testart, M.D., GSCG Chief Medical Officer.
Two courses are scheduled, one to be conducted in Santiago, Chile August 23-24, and the other in Cancun, Mexico October 11-12.
The training course involves facial fat transfer injection combined with adipose-derived stem cells, to address the primary issues that concern patients in the aesthetic field, including facial aging caused by volume loss.
Hoyos is a plastic surgeon and stem cell expert who founded Stemlab, a Bogota, Colombia facility that conducts extensive research in regenerative medicine in an effort to establish stem cell treatments that can repair damaged tissue in living organisms.
Alfredo Hoyos, MD
Testart is a surgeon specializing in child trauma microsurgery. He is also a medical entrepreneur and founder of Consortia Innovas S.A. in Santiago, Chile, an organization dedicated to consulting and clinical health management for clinical management firms and research and development-oriented planners on the latest treatments in regenerative medicine as they become available.
Enrique Testart, MD
Hoyos and Testart will train qualified physicians on cell assisted fat transfer techniques and protocols, during which fat cells are harvested from the patient’s own body and redistributed to other areas of the body to augment sunken or thin regions of the face or body in order to add volume where it is desired.
Lipoinjection for cosmetic treatments can be unpredictable, and has a low rate of graft survival due to partial necrosis. To overcome these problems, cell assisted fat transfer (lipostransfer) was developed as a strategy wherein autologous adipose-derived stem (stromal) cells (ASCs) are used in combination with lipoinjection. A stromal vascular fraction (SVF) containing ASCs is freshly isolated from half of the aspirated fat and recombined with the other half. This process converts relatively ASC-poor aspirated fat to ASC-rich fat, reducing postoperative atrophy of injected fat to a minimal level that clinical trials have found does not change substantially after 2 months. Patients walk away with soft and natural-appearing augmentation.
Cell assisted fat transfer is a promising treatment for facial rejuvenation and soft tissue augmentation because there are no incisional scars or complications associated with foreign materials.
The cell assisted fat transfer training course will be offered through Global Stem Cells Group affiliate Stem Cell
To learn more, visit the Global Stem Cells Group website, or the Stem Cell Training website, email 
About Global Stem Cell Group:
Global Stem Cells Group, Inc. is the parent company of six wholly owned operating companies dedicated entirely to stem cell research, training, products and solutions. Founded in 2012, the company combines dedicated researchers, physician and patient educators and solution providers with the shared goal of meeting the growing worldwide need for leading edge stem cell treatments and solutions. With a singular focus on this exciting new area of medical research, Global Stem Cells Group and its subsidiaries are uniquely positioned to become global leaders in cellular medicine.
About Stem Cell Training, Inc.:
Stem Cell Training, Inc. is a multi-disciplinary company offering coursework and training in 35 cities worldwide. The coursework offered focuses on minimally invasive techniques for harvesting stem cells from adipose tissue, bone marrow and platelet-rich plasma. By equipping physicians with these techniques, the goal is to enable them to return to their practices, better able to apply these techniques in patient treatments.
###
To view this press release live online, click here
- Published in Press Releases
University of Santiago to Endorse Asian-Pacific Symposium
MIAMI, April 30, 2016–Global Stem Cells Group has announced the University of Santiago’s plans to endorse an alliance between GSCG and the university’s Biotechnology Lab to host an Asian-Pacific Symposium and other initiatives for potential stem cell protocol management for 2016 – 2020. The symposium will be held July 1-2 at the university in Santiago, Chile.
In 2015, University of Santiago officials and top Global Stem Cells Group executives began meeting to establish a working agenda and foster initiatives to promote stem cell research and development as a collaborative effort.
Professor Alejandra Moenen, Ph.D., who heads the University of Santiago’s Biochemistry and Molecular Biology Department, and a team of Ph.D.s from the university will join Global Stem Cells Group to host the Asian-Pacific Symposium. Moenen is an internationally prominent researcher whose work in biological research has been published in 50 major scientific journals worldwide.
The symposium will concentrate on regenerative medicine and stem cell applications to anti-aging and aesthetic medicine. University of Santiago faculty will lead the symposium, and qualified academic and medical groups from around the world will be invited to present their scientific papers. Among them will be Duncan Ross, Ph.D., a Global Stem Cells Group Advisory Board member who will present his abstract, “The mechanism of action of stem cells in regenerative medicine is increasingly being understood to be effected through paracrine factors. Central to the question of when and how to treat an individual disease is where and for what duration a transplanted cell will persist to generate these factors.”
A meeting to confirm the Asia-Pacific Symposium alliance was attended by Kevin Maisey, Ph.D., and Jorge LaPorte, Ph.D., both representing the Biology and Biochemistry Department of the University of Santiago. University Dean Silvia Ferrada Vergara has validated the agreement, and the endorsement will be announced at the Asia-Pacific Conference in July.
For more information, visit the Global Stem Cells Group website, email bnovas(at)stemcellsgroup(dot)com, or call +1 305 560 5337.
About Global Stem Cell Group:
Global Stem Cells Group, Inc. is the parent company of six wholly owned operating companies dedicated entirely to stem cell research, training, products and solutions. Founded in 2012, the company combines dedicated researchers, physician and patient educators and solution providers with the shared goal of meeting the growing worldwide need for leading edge stem cell treatments and solutions. With a singular focus on this exciting new area of medical research, Global Stem Cells Group and its subsidiaries are uniquely positioned to become global leaders in cellular medicine.
Global Stem Cells Group’s corporate mission is to make the promise of stem cell medicine a reality for patients around the world. With each of GSCG’s six operating companies focused on a separate research-based mission, the result is a global network of state-of-the-art stem cell treatments.
About the University of Santiago:
Celebrating the 166th anniversary of its founding in 2016, the University of Santiago is one of the oldest and most traditional institutions of higher education in Chile. Offering 66 comprehensive undergraduate programs to more than 18,000 students, the university has seven faculties representing departments of Engineering, Humanities, Science, Business and Economics, Chemistry and Biology, Medical Sciences and Technology. The university us moving toward a new era of implementing improved and advanced master’s degree and doctoral degree programs, in addition to the numerous courses and postgraduate programs already in place in a variety of academic and research disciplines.
Since Chile’s 1981 higher education reform, the University of Santiago has concentrated its activities in the metropolitan area, with a particular focus on teaching, research and extension, carried out on the 34-hectare (84 acre) campus in the City of Santiago.
The University of Santiago is known for its participation in national and international projects and the contributions of its scholars to various fields of knowledge. A singular effort has been placed on linking the work of university researchers, who have a close relationship with the socio-economic needs of the country, to improve public health conditions in the country. The University of Santiago is one of Chile’s four Universities noted for successful fundraising efforts to support research and development.
###
To view this press release live online, click here
- Published in Press Releases
Global Stem Cells Group and Santiago University to Launch New Edition of Post-Graduate Diploma Program
MIAMI, April 30, 2015–Global Stem Cells Group and the University of Santiago, Chile have announced plans to launch a new edition of the post-graduate diploma program, “Diplomat in Cell Therapy and Tissue Engineering.” The first of its kind worldwide, the program is designed for physicians and qualified practitioners to bring stem cell therapies into the doctor’s office to treat patients.
The University of Santiago, ranked among the top universities in South America, is the first state university to offer a diploma program in stem cells, tissue engineering and cell therapy.
The program concentrates on advances in cell biology, the clinical and linked characteristics to bioprocessing of stem cells derived from adipose tissue, and other stem cell-based protocols. Based on medical research that emerged in the late 20th and early 21st centuries to give rise to stem cell therapies, this is a new form of medical treatment in which cells and tissues are used as healing elements, not only to supplement or replace deficient cells, but to induce regeneration and restoration of a lost biological order during the development of a disease or injury.
Alejandra Moenen, Ph.D., who heads the University of Santiago’s Biochemistry and Molecular Biology Department, was chosen to teach the program. Moenen is an internationally prominent researcher whose work in biological research has been published in 50 major scientific journals worldwide.
Global Stem Cells Group has established the program’s medical and scientific management team, headed by Duncan Ross, Ph.D. and Enrique Testart, M.D., to develop a theoretical and practical, 120 hour program that will deliver the fundamentals of the most advanced cell therapies and clinical applications currently practiced safely and effectively in more than 35 cities worldwide.
In a 2015 televised interview, Joseph Purita, M.D., an orthopedic surgeon, stem cell pioneer and founder of the American Academy of Regenerative Medicine, said that Santiago University has all the human and physical resources and conditions necessary to become the capital of stem cell research and advances in South America.
Purita’s foresight launched an alliance between GSCG and Santiago University that led way to building an academic program to meet the needs of physicians, engineers, biologists and biochemists required to move regenerative medicine forward.
The Diplomat in Cell Therapy and Tissue Engineering program will begin in 2016, with a first phase designed to carry it through 2020. A maximum of 15 students will make up groups who will occupy individual biological work stations, study electron microscopy, flow cytometry, real-time polymerase chain reaction (PCR) and faculty-arranged resources to make this international diploma program a recognized leader worldwide for the training of specialists in the field of stem cell medicine.
Open enrollment will begin April 30 for high-achieving medical professionals with qualified credentials, who will receive dual certification—a diploma in Cell Therapy and Tissue Engineering from the University of Santiago, and the American Certificate of Protocols from Global Stem Cells Group, and its affiliate, Stem Cell Training, Inc. The course will include practical, hands-on training during which students will apply stem cell harvesting and implantation techniques learned in the laboratory, quantify cell counts, weigh comparisons and ultimately experience stem cell therapy in all its dimensions, to use in different areas of medicine and dentistry.
“Between physicians, biologists, biochemists and engineers, we have collectively built a curriculum that is designed for the new generation of medicine,” says Testart, Global Stem Cells Group Chief Medical Officer. “But even more important, we will provide a new generation of patients with therapies that will enable them to improve their quality of life for years to come, and to enjoy the longevity given us in the modern world.”
“The Diplomat in Cell Therapy and Tissue Engineering program will offer medical professionals invaluable lessons in this new art of stem regenerative healing, as well as the scientific and practical methodologies involved in stem cell medicine,” says Benito Novas, Global Stem Cells Group CEO.
Educational strategies will be taught in theory and in practical hands-on classes, during which students can raise questions and work on problem solving.
For more information, visit the Global Stem Cells Group website, email bnovas(at)stemcellsgroup(dot)com, or call +1 305 560 5337.
About Global Stem Cells Group:
Global Stem Cells Group is the parent company of six wholly owned operating companies dedicated entirely to stem cell research, training, products and solutions. Founded in 2012, the company combines dedicated researchers, physician and patient educators and solution providers with the shared goal of meeting the growing worldwide need for leading edge stem cell treatments and solutions. With a singular focus on this exciting new area of medical research, Global Stem Cells Group and its subsidiaries are uniquely positioned to become global leaders in cellular medicine.
Global Stem Cells Group’s corporate mission is to make the promise of stem cell medicine a reality for patients around the world. With each of GSCG’s six operating companies focused on a separate research-based mission, the result is a global network of state-of-the-art stem cell treatments.
###
- Published in Press Releases
